• bioAffinity Technologies (NASDAQ:BIAF) reports a notable 62% revenue increase for CyPath Lung but faces mounting financial hurdles.
• The company showed an earnings per share (EPS) of -$0.17, underestimating the target of -$0.10, indicating financial loss.
• BIAF’s high price-to-sales ratio raises concerns regarding valuation and liquidity issues.

bioAffinity Technologies, trading as NASDAQ:BIAF, specializes in developing pioneering diagnostic products. Although CyPath Lung’s revenue has surged by 62% year-over-year in H1 2025, BIAF’s financial report from August 14, 2025, revealed significant challenges.

The reported earnings per share (EPS) stood at -0.17, which missed the anticipated -0.10. Currently, the company is therefore experiencing a financial deficit, highlighted by a price-to-earnings (P/E) ratio of approximately -0.42, indicating no profitability at present.

The overall revenue approximated $1.27 million, falling short of the forecast of $1.51 million. Despite the promising growth of CyPath Lung, the lack of sufficient revenue generation raises concerns for investors. The price-to-sales ratio nearing 0.82 signals that BIAF’s shares might be undervalued, potentially amplifying investor apprehension.

BIAF’s enterprise value to sales ratio hovers around 0.92, reinforcing the overall valuation challenges it faces. Additionally, an enterprise value to operating cash flow ratio of approximately -1.23 speaks to the difficulties tied to maintaining positive cash flow. The earnings yield reflects an unfavorable -2.37%, representing further financial stress.

The company operates with a moderate debt-to-equity ratio of about 0.92, but a current ratio of around 0.55 suggests potential liquidity challenges. This could pose obstacles as bioAffinity navigates through its current financial landscape.